Fig. 2.

Survival curve for time to relapse for participants randomized to either placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks stratified for (a) ‘no comorbid anxiety’ (n = 25) and (b) ‘comorbid anxiety’ (n = 17). Intention-to-treat analysis. In participants with ‘comorbid anxiety’, significant treatment effects (χ² = 12.43, P < 0.01) emerged between baclofen 30 mg/day and placebo (χ² = 9.10, P < 0.01) and baclofen 60 mg/day and placebo (χ² = 4.55, P < 0.05). Patients were categorized into two groups according to the absence or presence of an anxiety disorder (generalized anxiety disorder, social phobia, obsessive disorder, agoraphobia, panic disorder and/or PTSD) as per the Mini International Neuropsychiatric Interview conducted at baseline.